New cognitive assessment product

RNS Number : 6830N

Cambridge Cognition Holdings PLC

20 May 2015

 

20 May 2015

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

Development of Alzheimer's treatments to be accelerated with new Cambridge Cognition product

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests, announces the launch of a new cloud based cognitive assessment product to accelerate development of Alzheimer's disease treatments, Cantab Connect Alzheimer's.

The global market for Alzheimer's disease treatment is expected to more than double in value from $4.9 billion in 2013 to reach an estimated $13.3 billion by 2023, making the race to develop disease-modifying therapies big business for the pharmaceutical industry. In order to achieve this, more sensitive analytical tools are required to identify drugs that can alter the course of the disease. The Cantab Connect Alzheimer's cognitive assessment product provides sensitive measures that are far more effective than traditional paper-based tests, enabling pharmaceutical companies to increase the chances of identifying new drugs that have positive effects on Alzheimer's patients and gaining subsequent regulatory and market approval.

The market size of cognitive assessments in Alzheimer's disease trials is estimated to be in excess of $17m. With over thirty Alzheimer's trials already completed using proprietary Cambridge Cognition products, the Company forecast this to be an increasing area of growth potential following the launch of Cantab Connect Alzheimer's.

Nick Kerton, Chief Executive Officer of Cambridge Cognition Holdings plc commented: "Cambridge Cognition has become synonymous with innovation in healthcare, research and development for Alzheimer's. Today we launch the first in a series of cognitive assessment software products to support effective development of new drugs across a range of disease areas. With the capabilities of our cloud technology combined with acutely sensitive measures of brain function, pharmaceutical companies can now conduct large, objective and reliable studies in clinical development to combat the disease quicker."

Enquiries:

Cambridge Cognition Holdings plc	www.cambridgecognition.com
Nick Kerton, Chief Executive Officer	Tel: [phone]
Nick Walters, Chief Financial Officer
finnCap Ltd (Nomad and Broker)	Tel: [phone]
Geoff Nash/ Simon Hicks	(Corporate Finance)
Malar Velaigam	(Corporate Broking)
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
Lianne Cawthorne	Mob: [phone]

About Cambridge Cognition

Cambridge Cognition is a world leading provider of computerised cognitive assessment products.  The company's range of touch-screen CANTAB™ neuropsychological tests, highly validated over one thousand peer-reviewed publications, are used by both academic  scientists  in their research, and clinical researchers in the pharmaceutical industry, to maximise knowledge of cognitive function.  In addition, the company is committed to broadening the access to this technology and is developing clinical healthcare products to improve the monitoring, management and maintenance of cognitive health and wellbeing.  Using these assessments, clinicians can identify and stratify patients so that patient referrals are accurate and efficient, enabling health and social care providers to deliver more effective advice, treatments and care - leading to better outcomes for patients and their families. 

 

END

 

 

NRAUKUVRVBAVAAR